Amvuttra (vutrisiran) is a follow-up to Alnylam's earlier RNA interference (RNAi) ATTR amyloidosis therapy Onpattro (patisiran), which was cleared by NICE for NHS use in 2019, but offers a simpler ...

Alnylam Pharmaceuticals ALNY announced that the FDA has accepted its supplemental new drug application (sNDA) seeking the ...

AMVUTTRA, whose generic name is Vutrisiran, received FDA approval in June 2022 for the treatment of the polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis in adults.

Wolfe Research downgraded Alnylam (ALNY) to Underperform from Peer Perform with a $205 price target The firm cites expectations that the company will expand its approved Amvuttra into the much ...

Strong patient uptake of next-generation drug Amvuttra (for ATTR amyloidosis with polyneuropathy) is driving sales, accounting for $259 million of the quarter’s net product revenue, representing ...

Alnylam Pharmaceuticals ALNY announced that the FDA has accepted its supplemental new drug application (sNDA) seeking the label expansion of Amvuttra (vutrisiran) for review to treat ATTR ...

Alnylam's Amvuttra followed these results with a once per quarter subcutaneous injection, which can be administered at home, with reductions of 28% and 33% for overall mortality and cardiovascular ...

Continued growth momentum in total TTR, achieving global net product revenues for ONPATTRO and AMVUTTRA for the third quarter of $50 million and $259 million, respectively, which combined ...